These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17354579)

  • 1. Possible predictors of target lesion revascularization after drug-eluting stent implantation.
    Yanagi D; Shirai K; Mori K; Ike A; Costantini CO; Costantini CR; Nishikawa H; Miller N; Zhang B; Tsuchiya Y; Urata H; Saku K
    J Cardiol; 2007 Feb; 49(2):63-7. PubMed ID: 17354579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent.
    Maeng M; Okkels Jensen L; Rasmussen K; Flensted Lassen J; Romer Krusell L; Thayssen P; Thuesen L
    Heart; 2007 Jun; 93(6):694-7. PubMed ID: 17194711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.
    Elezi S; Dibra A; Mehilli J; Pache J; Wessely R; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Oct; 48(7):1304-9. PubMed ID: 17010786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry.
    Abe M; Kimura T; Morimoto T; Taniguchi T; Yamanaka F; Nakao K; Yagi N; Kokubu N; Kasahara Y; Kataoka Y; Otsuka Y; Kawamura A; Miyazaki S; Nakao K; Horiuchi K; Ito A; Hoshizaki H; Kawaguchi R; Setoguchi M; Inada T; Kishi K; Sakamoto H; Morioka N; Imai M; Shiomi H; Nonogi H; Mitsudo K;
    Circulation; 2010 Jul; 122(1):42-51. PubMed ID: 20566954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients.
    Xu B; Li JJ; Yang YJ; Ma WH; Chen JL; Qiao SB; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2006 Apr; 119(7):533-8. PubMed ID: 16620692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.
    Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent.
    Cosgrave J; Melzi G; Corbett S; Biondi-Zoccai GG; Babic R; Airoldi F; Chieffo A; Sangiorgi GM; Montorfano M; Michev I; Carlino M; Colombo A
    Am Heart J; 2007 Mar; 153(3):354-9. PubMed ID: 17307411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.
    Migliorini A; Moschi G; Vergara R; Parodi G; Carrabba N; Antoniucci D
    Catheter Cardiovasc Interv; 2006 Mar; 67(3):344-8. PubMed ID: 16489559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.
    Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III.
    Mehta RH; Leon MB; Sketch MH;
    Am J Cardiol; 2007 Oct; 100(8B):62M-70M. PubMed ID: 17950834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.